NCAM1 and non-Hodgkin lymphoma: Nine patients, seven with advanced Hodgkin’s disease (HD) and two with non-Hodgkin’s lymphomas (NHL) received from one to three doses of cells ranging from 1 × 109 to 10 × 109 CIK cells/infusion, with CD56+ CIK cells representing 8–58% (median 22%) of the total cell population in the final product.